September 24th 2024
During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses combination therapy with nivolumab plus ipilimumab and chemotherapy for patients with non–small cell lung cancer in the first article of a 2-part series.
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
RET Rearrangements in Non-Small Cell Lung Cancer
June 25th 2018Chromosomal rearrangements involving the gene that encodes the RET tyrosine kinase are known oncogenic drivers in 1% to 2% of patients with non–small cell lung cancer. These RET rearrangements occur with characteristic partners, most commonly KIF5B, but also CCDC6, NCOA, TRIM33, CUX1, KIAA1217, FRMD4A, and KIAA1468.
Read More
Application for Frontline Nivolumab/Ipilimumab in TMB-High NSCLC Accepted by FDA
June 22nd 2018A supplemental biologics license application has been accepted by the FDA seeking approval for the combination of nivolumab plus ipilimumab for the frontline treatment of patients with advanced non–small cell lung cancer with tumor mutational burden ≥10 mutations per megabase, according to Bristol-Myers Squibb, the manufacturer of both immune checkpoint inhibitors.
Read More
Efficiency in Cancer Costs Can be Achieved Without Sacrificing Quality, HICOR Report Finds
June 21st 2018The Hutchinson Institute for Cancer Outcomes Research released the first Community Care Cancer in Washington State: Quality and Cost Report to provide transparency for patients and health providers, establishing a more value-based care model.
Read More
Osimertinib Granted European Approval for Frontline Treatment of EGFR-mutant NSCLC
June 12th 2018Osimertinib (Tagrisso) has been approved by The European Commission as a frontline treatment for patients with <em>EGFR</em>-mutant locally-advanced or metastatic non–small cell lung cancer. The approval is based on data from the phase III FLAURA trial.
Read More
Refinements in the Use of Genomic Rearrangements Signals Exciting Times Ahead
June 11th 2018Robert L. Ferris, MD, PhD, Physician Editor-In-Chief of the Journal of Targeted Therapies, discusses genomic rearrangements and the allelic fraction of that genomic rearrangement as a major component of an individual’s cancer.
Read More
Oncology Experts Reflect on Key Takeaways from Data Presented at ASCO Annual Meeting
June 7th 2018The 2018 ASCO Annual Meeting was a great success, with over 40,000 people in attendance and over 5000 abstracts presented from June 1-5 in Chicago, Illinois. Data from several phase III trials in lung cancer were presented, with especially significant results in non–small cell lung cancer. Other big areas during this year’s meeting included breast, gastrointestinal, genitourinary, and hematologic cancers.
Read More
PFS Extended With Addition of Bevacizumab to Erlotinib in EGFR-Mutated NSCLC
June 6th 2018Upfront treatment with the combination of bevacizumab (Avastin) and erlotinib (Tarceva) is superior to erlotinib alone as for patients with non–small cell lung cancer harboring<em> EGFR</em> mutations, according to results of a preplanned interim analysis of the phase III study known as NEJ026.
Read More
Impact of Durvalumab as Consolidation Therapy in NSCLC
June 6th 2018Julie R. Brahmer, MD, associate professor of oncology and co-director of the Upper Aerodigestive Department at the Bloomberg Kimmel Institute for Cancer Immunotherapy, John Hopkins Medicine, discusses the change in standard of care for patients with stage III non–small cell lung cancer. Durvalumab was recently approved by the FDA as a consolidation therapy for patients with stage III locally-advanced, unresectable NSCLC who had not progressed following standard chemoradiotherapy.
Watch
Dacomitinib Proves Superior to Gefitinib as Frontline Treatment for EGFR-Mutant NSCLC
June 6th 2018The investigational second-generation tyrosine kinase inhibitor dacomitinib demonstrated an improved median overall survival of 34.1 months compared to 26.8 months with gefitinib as a first-line treatment for patients with advanced, <em>EGFR</em>-mutant non–small cell lung cancer, according to data from a open-label, phase III trial presented at the 2018 ASCO Annual Meeting.<sup>1</sup>
Read More